Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CRISPR Therapeutics AG (CRSP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results -PDUFA target action date of December 8, 2023, for SCD and March 30, 2024, for TDT-"
06/09/2023 4 George Simeon (Director) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Granted 13,000 options to buy @ $62.59, valued at $813.7k
06/09/2023 4 Behbahani Ali (Director) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Granted 13,000 options to buy @ $62.59, valued at $813.7k
06/09/2023 4 Treco Douglas A (Director) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Granted 13,000 options to buy @ $62.59, valued at $813.7k
06/09/2023 4 High Katherine A (Director) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Granted 13,000 options to buy @ $62.59, valued at $813.7k
06/09/2023 4 Greene John (Director) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Granted 13,000 options to buy @ $62.59, valued at $813.7k
06/09/2023 4 Fleming Harold Edward (Director) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Granted 13,000 options to buy @ $62.59, valued at $813.7k
06/09/2023 4 Fardis Maria (Director) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Granted 13,000 options to buy @ $62.59, valued at $813.7k
06/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "of der CRISPR Therapeutics AG CRISPR Therapeutics AG with registered office in mit Sitz in Zug Zug I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sitz, Dauer und Zweck der Gesellschaft Art. 1 Corporate Name, Principal Office and Duration Art. 1 Firma, Sitz und Dauer Under the name CRISPR Therapeutics AG Unter der Firma CRISPR Therapeutics AG there exists a Company which is subject to the provisions of art. 620 et seq. of the Swiss Code of Obligations with registered office in Zug. The duration of the Company is unlimited. besteht für unbeschränkte Dauer eine Aktiengesellschaft gemäss Art. 620 ff. OR mit Sitz in Zug. Art. 2 Purpose Art. 2 Zweck The purpose of the Company is the research and development in the field of pharmaceutical pro..."
06/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Accepts Biologics License Applications for exagamglogene autotemcel for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - First CRISPR gene-editing filings to be accepted for review by FDA",
"Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association Congress - Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - - Data continue to demonstrate transformative and durable benefit - - Safety profile consistent with busulfan conditioning and autologous hematopoietic stem cell transplant –"
06/01/2023 4 Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Sold 7,301 shares @ $63.6149, valued at $464.5k
Sold 5,999 shares @ $64.4577, valued at $386.7k
Sold 9,300 shares @ $65.63, valued at $610.4k
Sold 2,400 shares @ $66.8338, valued at $160.4k
Exercised 25,000 options to buy @ $19.12, valued at $478k
05/30/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 4 Morrow Phuong Khanh (Chief Medical Officer) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Paid exercise price by delivering 2,527 shares @ $65.91, valued at $166.6k
Exercised 6,938 restricted stock units @ $0
05/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results"
04/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/25/2023 144 Form 144 - Report of proposed sale of securities:
04/03/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023-"
03/31/2023 4 Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Sold 19,719 shares @ $44.3733, valued at $875k
Sold 5,281 shares @ $44.7844, valued at $236.5k
Exercised 25,000 options to buy @ $19.12, valued at $478k
03/29/2023 8-K Quarterly results
03/27/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "[***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601 of Regulation S-K. NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND CRISPR THERAPEUTICS AG Non-excLusive LICENSE AGREEMENT This NON-EXCLUSIVE LICENSE AGREEMENT is entered into as of March 23, 2023 by and between Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG . Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” RECITALS WHEREAS, CRISPR possesses certain Patents, Know-How, technology and exper...",
"Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes -Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- -CRISPR Therapeutics to receive $100M upfront payment plus milestone and royalty payments on potential future gene-edited hypoimmune T1D products -"
03/14/2023 4 Prasad Raju (CFO) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Granted 40,000 restricted stock units @ $0
Granted 100,000 options to buy @ $45.15, valued at $4.5M
03/14/2023 4 Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Paid exercise price by delivering 5,358 shares @ $43.22, valued at $231.6k
Paid exercise price by delivering 4,086 shares @ $43.22, valued at $176.6k
Exercised 11,833 restricted stock units @ $0
Granted 188,000 options to buy @ $43.22, valued at $8.1M
Granted 77,000 restricted stock units @ $0
Exercised 9,000 restricted stock units @ $0
03/14/2023 4 KASINGER JAMES R. (General Counsel and Secretary) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Paid exercise price by delivering 1,283 shares @ $43.22, valued at $55.5k
Paid exercise price by delivering 1,022 shares @ $43.22, valued at $44.2k
Exercised 2,833 restricted stock units @ $0
Granted 40,000 options to buy @ $43.22, valued at $1.7M
Granted 22,000 restricted stock units @ $0
Exercised 2,250 restricted stock units @ $0
03/14/2023 4 Morrow Phuong Khanh (Chief Medical Officer) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Granted 44,620 options to buy @ $43.22, valued at $1.9M
Granted 22,000 restricted stock units @ $0
03/14/2023 3 Prasad Raju (CFO) has filed a Form 3 on CRISPR Therapeutics AG
03/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Proprietary Information and Inventions Agreement 16",
"Investor Contact:"
03/01/2023 4 Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG
Txns: Sold 10,180 shares @ $47.7122, valued at $485.7k
Sold 13,720 shares @ $48.5725, valued at $666.4k
Sold 1,100 shares @ $49.1986, valued at $54.1k
Exercised 25,000 options to buy @ $19.12, valued at $478k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy